177 related articles for article (PubMed ID: 30496464)
1. Transformation Morphisms and Time-to-Extinction Analysis That Map Therapy Duration From Preclinical Models to Patients With Tuberculosis: Translating From Apples to Oranges.
Magombedze G; Pasipanodya JG; Srivastava S; Deshpande D; Visser ME; Chigutsa E; McIlleron H; Gumbo T
Clin Infect Dis; 2018 Nov; 67(suppl_3):S349-S358. PubMed ID: 30496464
[TBL] [Abstract][Full Text] [Related]
2. Efficacy Versus Hepatotoxicity of High-dose Rifampin, Pyrazinamide, and Moxifloxacin to Shorten Tuberculosis Therapy Duration: There Is Still Fight in the Old Warriors Yet!
Srivastava S; Deshpande D; Magombedze G; Gumbo T
Clin Infect Dis; 2018 Nov; 67(suppl_3):S359-S364. PubMed ID: 30496465
[TBL] [Abstract][Full Text] [Related]
3. Duration of pretomanid/moxifloxacin/pyrazinamide therapy compared with standard therapy based on time-to-extinction mathematics.
Srivastava S; Deshpande D; Magombedze G; van Zyl J; Cirrincione K; Martin K; Bendet P; Berg A; Hanna D; Romero K; Hermann D; Gumbo T
J Antimicrob Chemother; 2020 Feb; 75(2):392-399. PubMed ID: 31713607
[TBL] [Abstract][Full Text] [Related]
4. Nouveau short-course therapy and morphism mapping for clinical pulmonary
Srivastava S; Wang JY; Magombedze G; Chapagain M; Huang HL; Deshpande D; Heysell SK; Pasipanodya JG; Gumbo T
Antimicrob Agents Chemother; 2023 May; 95(5):. PubMed ID: 33558291
[TBL] [Abstract][Full Text] [Related]
5. Shortened treatment regimens versus the standard regimen for drug-sensitive pulmonary tuberculosis.
Grace AG; Mittal A; Jain S; Tripathy JP; Satyanarayana S; Tharyan P; Kirubakaran R
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012918. PubMed ID: 31828771
[TBL] [Abstract][Full Text] [Related]
6. Correlations Between the Hollow Fiber Model of Tuberculosis and Therapeutic Events in Tuberculosis Patients: Learn and Confirm.
Gumbo T; Pasipanodya JG; Nuermberger E; Romero K; Hanna D
Clin Infect Dis; 2015 Aug; 61 Suppl 1():S18-24. PubMed ID: 26224768
[TBL] [Abstract][Full Text] [Related]
7. Moxifloxacin Replacement in Contemporary Tuberculosis Drug Regimens Is Ineffective against Persistent Mycobacterium tuberculosis in the Cornell Mouse Model.
Liu Y; Pertinez H; Davies GR; Gillespie SH; Coates AR; Hu Y
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29661869
[TBL] [Abstract][Full Text] [Related]
8. Systematic Analysis of Hollow Fiber Model of Tuberculosis Experiments.
Pasipanodya JG; Nuermberger E; Romero K; Hanna D; Gumbo T
Clin Infect Dis; 2015 Aug; 61 Suppl 1():S10-7. PubMed ID: 26224767
[TBL] [Abstract][Full Text] [Related]
9. Hollow-fibre system model of tuberculosis reproducibility and performance specifications for best practice in drug and combination therapy development.
Gumbo T; Srivastava S; Deshpande D; Pasipanodya JG; Berg A; Romero K; Hermann D; Hanna D
J Antimicrob Chemother; 2023 Apr; 78(4):953-964. PubMed ID: 36794692
[TBL] [Abstract][Full Text] [Related]
10.
Swaminath S; Paul A; Pradhan A; Sebastian J; Nair RR; Ajitkumar P
Microbiology (Reading); 2020 Feb; 166(2):180-198. PubMed ID: 31746727
[TBL] [Abstract][Full Text] [Related]
11. Impact of iron loading on the activity of isoniazid or ethambutol in the treatment of murine tuberculosis.
Lounis N; Maslo C; Truffot-Pernot C; Grosset J; Boelaert RJ
Int J Tuberc Lung Dis; 2003 Jun; 7(6):575-9. PubMed ID: 12797701
[TBL] [Abstract][Full Text] [Related]
12. Activity of Moxifloxacin against
Louie A; Duncanson B; Myrick J; Maynard M; Nole J; Brown D; Schmidt S; Neely M; Scanga CA; Peloquin C; Drusano GL
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249693
[TBL] [Abstract][Full Text] [Related]
13. Viable Mycobacterium tuberculosis in sputum after pulmonary tuberculosis cure.
Ambreen A; Jamil M; Rahman MAU; Mustafa T
BMC Infect Dis; 2019 Oct; 19(1):923. PubMed ID: 31666021
[TBL] [Abstract][Full Text] [Related]
14. Predicting the Outcomes of New Short-Course Regimens for Multidrug-Resistant Tuberculosis Using Intrahost and Pharmacokinetic-Pharmacodynamic Modeling.
Doan TN; Cao P; Emeto TI; McCaw JM; McBryde ES
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249697
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of isoniazid-induced expression of Mycobacterium tuberculosis antigen 85 in sputum: potential surrogate marker in tuberculosis chemotherapy trials.
Wallis RS; Phillips M; Johnson JL; Teixeira L; Rocha LM; Maciel E; Rose L; Wells C; Palaci M; Dietze R; Eisenach K; Ellner JJ
Antimicrob Agents Chemother; 2001 Apr; 45(4):1302-4. PubMed ID: 11257053
[TBL] [Abstract][Full Text] [Related]
16. Toxicity associated with tuberculosis chemotherapy in the REMoxTB study.
Tweed CD; Crook AM; Amukoye EI; Dawson R; Diacon AH; Hanekom M; McHugh TD; Mendel CM; Meredith SK; Murphy ME; Murthy SE; Nunn AJ; Phillips PPJ; Singh KP; Spigelman M; Wills GH; Gillespie SH
BMC Infect Dis; 2018 Jul; 18(1):317. PubMed ID: 29996783
[TBL] [Abstract][Full Text] [Related]
17. First-line anti-tuberculosis drug resistance trends of Mycobacterium tuberculosis complex isolates. A tertiary hospital study in Turkey.
Yazısız H; Hırçın Cenger D; Yazısız V; Kılıç L; Altın S
Tuberk Toraks; 2019 Jun; 67(2):92-101. PubMed ID: 31414639
[TBL] [Abstract][Full Text] [Related]
18. Early bactericidal activity of a moxifloxacin and isoniazid combination in smear-positive pulmonary tuberculosis.
Gillespie SH; Gosling RD; Uiso L; Sam NE; Kanduma EG; McHugh TD
J Antimicrob Chemother; 2005 Dec; 56(6):1169-71. PubMed ID: 16223939
[TBL] [Abstract][Full Text] [Related]
19. Molecular mechanism of the synergistic activity of ethambutol and isoniazid against
Zhu C; Liu Y; Hu L; Yang M; He ZG
J Biol Chem; 2018 Oct; 293(43):16741-16750. PubMed ID: 30185616
[TBL] [Abstract][Full Text] [Related]
20. Isoniazid Monoresistance and Rate of Culture Conversion among Patients in the State of Georgia with Confirmed Tuberculosis, 2009-2014.
Salindri AD; Sales RF; DiMiceli L; Schechter MC; Kempker RR; Magee MJ
Ann Am Thorac Soc; 2018 Mar; 15(3):331-340. PubMed ID: 29131662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
